Helixgate

Helixgate

Uncategorized

Opinion: AI doctors should be licensed. Here’s a framework to do that

Late last month, Utah’s Medical Licensing Board called for the immediate suspension of the state’s pilot program with the AI company Doctronic. The program lets a chatbot evaluate patients and recommend prescription renewals for nearly 200 chronic condition drugs, with the state planning to phase out physician review of each case.

The board said that it only learned about the pilot after it had launched. Its warning was blunt: proceeding without proper clinical oversight “potentially places Utah citizens at risk.”

Read the rest…

Read More

Published

on

Late last month, Utah’s Medical Licensing Board called for the immediate suspension of the state’s pilot program with the AI company Doctronic. The program lets a chatbot evaluate patients and recommend prescription renewals for nearly 200 chronic condition drugs, with the state planning to phase out physician review of each case.

The board said that it only learned about the pilot after it had launched. Its warning was blunt: proceeding without proper clinical oversight “potentially places Utah citizens at risk.”

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Advances in RSV Vaccine Research and Development

Advances in RSV Vaccine Research and Development

Published

on

Epidemiology, Next-Generation Vaccine Platforms, and the Critical Role of Prefusion F Antigens in RSV Research​ ​Read More

Continue Reading

Uncategorized

Published FDA rejections point to manufacturing, data gaps as key stumbling blocks

Published

on

The FDA’s decision last year to make complete response letters public provides new insight into why therapies sometimes fail to get the regulatory greenlight. Analysts say the information could help sponsors refine their regulatory strategies.

Continue Reading

Uncategorized

Merck, Amgen double down on bad cholesterol to vanquish number 1 killer

Merck, Amgen double down on bad cholesterol to vanquish number 1 killer

Published

on

New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on maintaining low levels of two key lipoproteins. Big pharma is all in, looking to improve on the standard statins to help vanquish America’s number one killer: heart disease.​ ​Read More

Continue Reading
Advertisement

Trending